

CANCER THERANOSTICS



EDITED BY


Xiaoyuan Chen
Stephen T. C. Wong



CANCER THERANOSTICS

Edited by

XIAOYUAN CHEN
STEPHEN WONG



AMSTERDAM • BOSTON • HEIDELBERG • LONDON
NEW YORK • OXFORD • PARIS • SAN DIEGO
SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO

Academic Press is an imprint of Elsevier



Academic Press is an imprint of Elsevier
525 B Street, Suite 1800, San Diego, CA 92101-4495, USA
32 Jamestown Road, London NW1 7BY, UK
225 Wyman Street, Waltham, MA 02451, USA

Copyright © 2014 Elsevier Inc. All rights reserved.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the publisher.

Permissions may be sought directly from Elsevier's Science & Technology Rights, Department in Oxford, UK: phone (+44) (0) 1865 843830; fax (+44) (0) 1865 853333; email: permissions@elsevier.com. Alternatively, visit the Science and Technology Books website at www.elsevierdirect.com/rights for further information.

Notice

No responsibility is assumed by the publisher for any injury and/or damage to persons, or property as a matter of products liability, negligence or otherwise, or from any use or, operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.

British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library

Library of Congress Cataloging-in-Publication Data

A catalog record for this book is available from the Library of Congress

ISBN: 978-0-12-407722-5

For information on all Academic Press publications
visit our website at elsevierdirect.com

Printed and bound by CPI Group (UK) Ltd, Croydon, CR0 4YY

14 15 16 17 18 10 9 8 7 6 5 4 3 2 1



Working together
to grow libraries in
developing countries

www.elsevier.com • www.bookaid.org

CANCER THERANOSTICS

Preface

The term “theranostics” has been used by many different people in a variety of contexts. Over the past decade, the field of theranostics has evolved considerably and has seen spectacular advances in biomarker identification, new molecular imaging probes and techniques, imaging guided molecular therapy, and novel nanotheranostics. The field is ripe to transform medicine as a whole and a greater dissemination of this knowledge can only speed its rate of acceptance and improvement. New physicians, researchers, and students working in this multidisciplinary field often ask how to blend *in vitro* diagnostics, *in vivo* imaging and therapy together for personalized medicine, and express the desire to have an authoritative textbook. This textbook, the first of its kind, is designed specifically to meet that demand, and is published in time to meet the needs of medical researchers in a comprehensive manner encompassing diagnostics, *in vivo* imaging and its use for image-guided therapy, and a variety of other miscellaneous subjects. To accomplish this daunting task we had the good fortune to recruit nearly 60 leaders in the field worldwide contributing to the twenty-six chapters.

Given the multidisciplinary nature of the field, the book is broken into five different sections. Part I (*In vitro* Diagnostics) consists of three chapters. Many theranostic approaches for cancer are based on analysis of tumor biopsy samples removed from the patient and analyzed in a laboratory setting. Chapter 1 defines the term “theranostics” and provides an overview of the specific aspects of cancer theranostics. Chapter 2 reviews the advanced biotechnology and computational biology efforts necessary to identify novel genomic biomarkers needed for developing targeted imaging probes and therapeutics. Chapter 3 describes the application of bioinformatics methods to discover proteomic biomarkers that are helpful for early tumor diagnosis, prognosis, and treatment.

Part II (Molecular Imaging) consists of Chapters 4–9. Numerous advances have been made in recent years in exogenous probes that allow precise and specific imaging of cancer *in situ* as well as label-free clinical imaging approaches. Chapter 4 summarizes the major radionuclide imaging procedures employed in assessing treatment response in patients with cancer. Chapter 5 focuses on the design of near-infrared fluorescent probes for

optical imaging-guided cancer diagnosis and treatment. Chapter 6 provides a concise review of optical bioluminescence imaging in the preclinical evaluation of tumors in response to various cancer therapies. Chapter 7 highlights the role of magnetic resonance imaging (MRI) in clinical and experimental oncology to characterize tumor structure, cell density, blood volume/flow, vessel permeability, viable/necrotic components, and metabolic changes. Chapter 8 exploits the potential of ultrasound imaging at morphological, functional and molecular levels for cancer treatment response assessment. Chapter 9 discusses the recent development of photoacoustic imaging (PAI) to provide functional and molecular information about tumor tissue and the applications of PAI in cancer therapies.

Part III (Imaging-Guided Therapy) is composed of Chapters 10–13 and describes how advanced imaging techniques now make highly precise surgical intervention possible. Chapter 10 reveals how the recent advancement of image-guided intervention techniques allows real-time visualization of the device and patient anatomy for efficient, accurate, and safe intervention procedures. Chapter 11 describes the emerging coherent anti-Stokes Raman scattering (CARS) imaging technique that combines label-free molecular vibrational imaging and automated image quantitation for intraoperative characterization of cancer lesions. Chapter 12 reviews oncologic application of multimodality image-guided treatment (MIGT) in theory and in practice. Chapter 13 introduces medical robotics for cellular and molecular imaging of cancer.

Part IV (Theranostic Platforms) consists of Chapters 14–22. The ultimate application of theranostics is to diagnose, treat, and monitor a local disorder using a single platform. Chapter 14 discusses the application of light in medicine and the role of porphyrins in photonic diagnostics and interventions, as well as applications beyond photonics and strategies for improving their utilization in oncology. Chapter 15 addresses the fundamental design and characteristics of magnetic nanoparticles and their attributes in magnetic resonance imaging and alternating magnetic fields. Chapter 16 emphasizes the potential of ultrasound-mediated drug and gene delivery strategies as a means of controlled release of therapeutic cargos by either acoustic cavitation or hyperthermia. Chapter 17

introduces imaging and therapeutic radionuclides as well as respective radiopharmaceutical agents used internally in nuclear medicine. Chapter 18 summarizes the basic properties of gold-based nanoparticles and highlights their recent advances as multifunctional platforms in cancer theranostics. Chapter 19 summarizes the unique physical, chemical, and mechanical characteristics of carbon nanomaterials for multimodality imaging, photothermal therapy and drug/gene delivery. Chapter 20 presents some of the recent advances in the development of silica nanoparticle based co-delivery of therapeutic and imaging contrast agents. Chapter 21 explores the design, synthesis, and application of photoluminescent semiconductor nanocrystals, or quantum dots (QDs) for traceable therapeutic delivery using optical imaging. Chapter 22 reviews the development of polymer- and protein-based nanoparticle platforms for theranostic applications and discusses the opportunities and challenges that the clinical translation of such nanoparticle platforms may encounter.

Part V (Other) consists of Chapter 23–26 and covers a number of informative topics that were too important to be left out. Chapter 23 is an overview of the regulatory aspects of cancer theranostics and discusses the ethics of human subject protection and FDA review of investigational drugs and devices as they relate to theranostics. Chapter 24 summarizes the current preparation processes of various theranostic nanoparticles at a lab scale, the scaling-up methods, and

corresponding pilot plants of nanoparticle production. Chapter 25 provides an overview of commercialization of nanotechnology, nanomedicine, and theranostic nanomedicine (nanotheranostics) as a foundation for understanding the challenges of bringing theranostics to market. Chapter 26 introduces the origins of cell heterogeneity in cancer and discusses how this emerging knowledge has shed light on the difficulties encountered in the management of neoplasias over the past few decades.

It is impossible to describe all the areas that theranostics has had, or will have, an impact on the science and practice of personalized medicine. It is not our aim to offer up a complete solution to combined cancer diagnosis and therapy, but to give readers a sense of the opportunities and challenges in this relatively new field. It has been a great pleasure working with the authors of this book. Without their enthusiasm, encouragement and professional delivery of their contributions in a timely manner, it would not have been possible to make this book a reality. Although this book focuses on cancer theranostics, many of the concepts and principles described are applicable to other disease types. We hope that this book may form a foundation for further advances in the field of theranostics.

Xiaoyuan (Shawn) Chen, PhD

Stephen T.C. Wong, PhD, PE

Acknowledgments

Both editors are grateful to their institutions and departments for the continuing support that enabled this work. We truly appreciate the excellent contributions of more than sixty scientists and clinicians who sacrificed much of their precious time to the creation of this book. It is really our great fortune for us to be able to lend the expertise of a team of international leaders of their fields.

Special thanks to Consulting Publisher Wayne Yuhasz for his kind invitation to edit this book, Associate Acquisitions Editor Catherine Van Der Laan

for her tremendous efforts in helping us assemble this book, freelance Project Manager Melissa Read for the production of this book, as well as other talented staff at Elsevier throughout the planning and writing.

Organizing and editing this book volume was primarily done out of our normal working hours, which had an enormous impact on family time. Both editors are indebted to their wives and children and thank them for their support, constant encouragement, and patience.

About the Editors



Dr. Xiaoyuan (Shawn) Chen is a Senior Investigator and Chief of the Laboratory of Molecular Imaging and Nanomedicine (LOMIN) at the National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH). His current research interests include development of molecular imaging toolbox for better understanding of biology, early diagnosis of disease, monitoring therapy response, and guiding drug discovery/development. His lab puts special emphasis on high-sensitivity nanosensors for biomarker detection and theranostic nanomedicine for imaging, gene and drug delivery, and monitoring of treatment. He received his BS (1993) and MS (1996) in chemistry from Nanjing University and PhD (1999) in chemistry from the University of Idaho. Dr. Chen has published over 400 peer-reviewed papers (H-index = 74, total citations > 20,000, over 50 papers with $IF \geq 10$) and numerous books and book chapters. He is the founding editor of journal *Theranostics* (2012 IF = 7.8).



Dr. Stephen Wong is the Founding Chair for Department of Systems Medicine and Bioengineering, Houston Methodist Research Institute (HRMI). He holds the John S. Dunn Distinguished Endowed Chair in Biomedical Engineering. He is a Professor of Radiology, Neurosciences, Pathology and Laboratory Medicine at Weill Cornell Medical College; Director of Translational Research at Methodist Cancer Center, Chief of Medical Physics and Chief Research Information Officer at Houston Methodist Hospital. He also serves as the Director of the Chao Center for BRAIN and of the NCI Center for Modeling Cancer Development at HMRI. Dr. Wong has over 25 years of experience in academia and industry, including Hewlett Packard, AT&T Bell Labs, Philips Medical Systems, Charles Schwab, UCSF, Harvard Medical School and made original contributions in medical imaging, biomedical informatics, drug repositioning, and electronics. He has published over 400 peer-reviewed papers. He received his BEng in Electrical Engineering with honors from the University of Western Australia, MSc and PhD in Computer Science from Lehigh University, and senior executive education from Stanford University, Columbia University, and MIT. He is a licensed professional engineer.

List of Contributors

- Archie A. Alexander** James K. Elrod Department of Health Administration, Louisiana State University, Shreveport, Louisiana, U.S.A.
- Miguel Valdivia y Alvarado** Houston Methodist Research Institute, Weill Cornell Medical College, Texas, U.S.A.
- Emma L.B. Anquillare** Laboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, U.S.A.
- Tobias Bäuerle** Department of Medical Physics in Radiology, German Cancer Research Center, Heidelberg, Germany; University Hospital Erlangen, Institute of Radiology, Maximiliansplatz 1, 91054 Erlangen, Germany
- Weibo Cai** Department of Radiology, University of Wisconsin—Madison, Madison, Wisconsin, U.S.A.; Department of Medical Physics, University of Wisconsin—Madison, Madison, Wisconsin, U.S.A.; University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, U.S.A.
- Warren C.W. Chan** Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Canada; Donnelly Centre for Cellular and Biomedical Research, Department of Chemical Engineering, Department of Chemistry, Department of Materials Science and Engineering, University of Toronto, Toronto, Canada
- Tou Pin Chang** The Hamlyn Centre for Robotic Surgery, Imperial College, London, U.K.
- Chin-Tu Chen** Department of Radiology, University of Chicago, Chicago, Illinois, U.S.A.
- Feng Chen** Theragnostic Laboratory, Department of Imaging and Pathology, University Hospital, University of Leuven, Leuven, Belgium; Department of Radiology, First Affiliated Hospital, Zhejiang University Hangzhou, Zhejiang, China
- Jingyi Chen** Department of Chemistry and Biochemistry, University of Arkansas, Fayetteville, Arkansas, U.S.A.
- Nai-Tzu Chen** Division of Medical Engineering Research, National Health Research Institutes, Zhunan Town, Miaoli County, Taiwan
- Xiaoyuan Chen** Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, Maryland, U.S.A.
- Yun-Sheng Chen** Department of Biomedical Engineering, University of Texas at Austin, Austin, Texas, U.S.A.; Department of Electrical and Computer Engineering, University of Texas at Austin, Austin, Texas, U.S.A.
- Shih-Hsun Cheng** Division of Medical Engineering Research, National Health Research Institutes, Zhunan Town, Miaoli County, Taiwan
- Gi Hyun Choi** Department of Maxillofacial Biomedical Engineering & Institute of Oral Biology, School of Dentistry, Kyung Hee University, Seoul, Republic of Korea
- Mary K. Clancy** Office of Research Protection, Methodist Hospital Research Institute, Houston, Texas, U.S.A.
- Stanislav Y. Emelianov** Department of Biomedical Engineering, University of Texas at Austin, Austin, Texas, U.S.A.; Department of Electrical and Computer Engineering, University of Texas at Austin, Austin, Texas, U.S.A.
- Omid C. Farokhzad** Laboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, U.S.A.
- Liang Gao** Chroma Technology Corporation, Bellows Falls, Vermont, U.S.A.
- Tiancheng He** Houston Methodist Research Institute, Weill Cornell Medical College, Texas, U.S.A.
- Dong Nyoung Heo** Department of Maxillofacial Biomedical Engineering & Institute of Oral Biology, School of Dentistry, Kyung Hee University, Seoul, Republic of Korea
- Marshall E. Hicks** University of Texas M.D. Anderson Cancer Center, Houston, Texas, U.S.A.
- Don N. Ho** Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, Maryland, U.S.A.
- Kurt B. Hodges** Department of Basic Medical Sciences and Center for Cancer Research, Purdue University, West Lafayette, Indiana, U.S.A.; Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana, U.S.A.
- Shao-Ling Huang** Division of Cardiology, Department of Internal Medicine, University of Texas at Houston Medical School, and Center for Clinical and Translational Sciences, University of Texas Health Science Center at Houston, Houston, Texas, U.S.A.
- Elizabeth Huynh** Ontario Cancer Institute and Techna Institute, UHN, Toronto, Canada; Department of Medical Biophysics, University of Toronto, Toronto, Canada
- Hossein Jadvar** Keck School of Medicine of USC, University of Southern California, Los Angeles, California, U.S.A.
- Guangxu Jin** Department of Systems Medicine and Bioengineering, The Methodist Hospital Research Institute, Weill Cornell Medical College, Houston, Texas, U.S.A.
- Fabrice Jotterand** Institute of Biomedical Ethics, University of Basel, Switzerland
- Dorde Komljenovic** Department of Medical Physics in Radiology, German Cancer Research Center, Heidelberg, Germany

- Il Keun Kwon** Department of Maxillofacial Biomedical Engineering & Institute of Oral Biology, School of Dentistry, Kyung Hee University, Seoul, Republic of Korea
- Sang Cheon Lee** Department of Maxillofacial Biomedical Engineering & Institute of Oral Biology, School of Dentistry, Kyung Hee University, Seoul, Republic of Korea
- Sophie A. Lelièvre** Department of Basic Medical Sciences and Center for Cancer Research, Purdue University, West Lafayette, Indiana, U.S.A.
- Fuhai Li** Department of Systems Medicine and Bioengineering, Houston Methodist Hospital Research Institute, Weill Cornell Medical College, Houston, Texas, U.S.A.
- Gang Liu** State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen, China; Sichuan Key Laboratory of Medical Imaging, North Sichuan Medical College, Nanchong, China
- Tracy W. Liu** Ontario Cancer Institute and Techna Institute, UHN, Toronto, Canada; Department of Medical Biophysics, University of Toronto, Toronto, Canada
- Leu-Wei Lo** Division of Medical Engineering Research, National Health Research Institutes, Zhunan Town, Miaoli County, Taiwan
- Kongkuo Lu** Philips Research North America, New York, U.S.A.
- Thomas D. MacDonald** Department of Pharmaceutical Sciences, University of Toronto, Toronto, Canada; Ontario Cancer Institute and Techna Institute, UHN, Toronto, Canada
- James J. Mancuso** Department of Systems Medicine and Bioengineering, Houston Methodist Hospital Research Institute, Weill Cornell Medical College, Houston, Texas, U.S.A.
- David D. McPherson** Division of Cardiology, Department of Internal Medicine, University of Texas at Houston Medical School, and Center for Clinical and Translational Sciences, University of Texas Health Science Center at Houston, Houston, Texas, U.S.A.
- Kung Hyun Min** Department of Life and Nanopharmaceutical Science, Kyung Hee University, Seoul, Republic of Korea
- Tapas R. Nayak** Department of Radiology, University of Wisconsin–Madison, Madison, Wisconsin, U.S.A.
- Yicheng Ni** Theragnostic Laboratory, Department of Imaging and Pathology, University Hospital, KU Leuven, Leuven, Belgium
- Kinam Park** Department of Maxillofacial Biomedical Engineering & Institute of Oral Biology, School of Dentistry, Kyung Hee University, Seoul, Republic of Korea
- Ramasamy Paulmurugan** Molecular Imaging Program at Stanford, Bio-X Program, Stanford University School of Medicine, Stanford, California, U.S.A.
- Thillai V. Sekar** Molecular Imaging Program at Stanford, Bio-X Program, Stanford University School of Medicine, Stanford, California, U.S.A.
- Jinjun Shi** Laboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, U.S.A.
- Jeffrey S. Souris** Department of Radiology, University of Chicago, Chicago, Illinois, U.S.A.
- Hongying Su** Department of Chemical Engineering, Kunming University of Science and Technology, Kunming, China; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen, China
- Pierre-Alexandre Vidi** Department of Basic Medical Sciences and Center for Cancer Research, Purdue University, West Lafayette, Indiana, U.S.A.
- Carl D. Walkey** Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Canada
- Zhantong Wang** State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen, China
- Franklin C. Wong** University of Texas M.D. Anderson Cancer Center, Houston, Texas, U.S.A.
- Stephen T.C. Wong** Department of Systems Medicine and Bioengineering, Houston Methodist Hospital Research Institute, Weill Cornell Medical College, Houston, Texas, U.S.A.
- Zhong Xue** Houston Methodist Research Institute, Weill Cornell Medical College, Texas, U.S.A.
- Sheng Xu** National Institutes of Health, Bethesda, Maryland, U.S.A.
- Guang-Zhong Yang** The Hamlyn Centre for Robotic Surgery, Imperial College London, U.K.
- Doug Yeager** Department of Biomedical Engineering, University of Texas at Austin, Austin, Texas, U.S.A.
- Zheng Yin** Department of Systems Medicine and Bioengineering, Houston Methodist Hospital Research Institute, Weill Cornell Medical College, Houston, Texas, U.S.A.
- Yin Zhang** Department of Medical Physics, University of Wisconsin–Madison, Madison, Wisconsin, U.S.A.
- Gang Zheng** Department of Pharmaceutical Sciences, University of Toronto, Toronto, Canada; Ontario Cancer Institute and Techna Institute, UHN, Toronto, Canada; Department of Pharmaceutical Sciences, University of Toronto, Toronto, Canada
- Xi Zhu** Laboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, U.S.A.; Key Laboratory of Drug Targeting and Drug Delivery System, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, Sichuan, China

Contents

Preface	ix
Acknowledgments	xi
About the Editors	xiii
List of Contributors	xv

I

IN VITRO DIAGNOSTICS

1. Cancer Theranostics: An Introduction

XIAOYUAN CHEN AND STEPHEN T.C. WONG

Cancer Theranostics: A Definition	3
Theranostic Cancer Biomarkers	4
Molecular Imaging in Cancer Theranostics	4
Imaging-Guided Cancer Therapy	5
Theranostic Platforms	5
Challenges and Future Perspectives	7
References	7

2. Genomics-Based Cancer Theranostics

ZHENG YIN, JAMES J. MANCUSO, FUHAI LI AND STEPHEN T.C. WONG

Introduction	9
Next Generation Sequencing Technology for Genomics-Based Cancer Theranostics	11
Genomics Landscapes in Common Forms of Human Cancers	13
Functions of Key Signaling Pathways in Cancer	15
Integration of Genomic Screening for Cancer Theranostics	16
Acknowledgments	18
Glossary	18
Abbreviations	18
References	18

3. Proteomics-Based Theranostics

GUANGXU JIN AND STEPHEN T.C. WONG

Introduction	21
Mass Spectrometry Techniques Used for Proteomics Biomarker Discovery	23
Bioinformatics Analysis Pipeline for Proteomics Biomarker Discovery	24
Challenges in Proteomics Biomarker Discovery	30
Existing Single Biomarkers	31
Knowledge-Integrated Network Biomarker Discovery	31
Clinical Validation of Proteomics Biomarkers	36
Glossary	37
Abbreviations	37
References	37

II

MOLECULAR IMAGING

4. Radionuclide Imaging of Cancer Therapy

HOSSEIN JADVAR

Bone Scintigraphy	45
Thyroid Radioiodine Scintigraphy	46
Nonspecific Single-Photon Radiotracers	46
Positron Emission Tomography	47
Conclusion	52
References	52

5. Near-Infrared Fluorescence Imaging Probes for Cancer Diagnosis and Treatment

HONGYING SU, ZHANTONG WANG AND GANG LIU

Introduction	55
Antibody-Based NIR Probes	56
Peptide-Based NIR Probes	56
Aptamer-Based NIR Probes	58
Polymer-Based NIR Probes	59
Lipid-Based NIR Probes	59
Functional Quantum Dots	60
Functional Upconversion Nanoparticles	62
Clinical Applications and Perspectives	62
Conclusions	64
Acknowledgments	64
References	64

6. Bioluminescence Imaging of Cancer Therapy

THILLAI V. SEKAR AND RAMASAMY PAULMURUGAN

Introduction	70
Preclinical Bioluminescence Imaging for Monitoring Cancer Therapy	77
Therapeutic Evaluation in Rat	87
Conclusion	89
References	89

7. Magnetic Resonance Imaging of Cancer Therapy

FENG CHEN AND YICHENG NI

New Trends of Cancer Therapies	95
MR Imaging in Translational Cancer Therapy	101
Necrosis MR Imaging: A Potential Platform for Developing Cancer Theranostics	118
Acknowledgments	122
Abbreviations	122
References	122

8. Ultrasound Imaging of Cancer Therapy

DORDE KOMLJENOVIC AND TOBIAS BÄUERLE

Introduction	127
Ultrasound Imaging Concepts	129
Assessment of Cancer Therapy	131
Conclusion	135
Acknowledgments	135
Abbreviations	135
Glossary	136
References	136

9. Photoacoustic Imaging for Cancer Diagnosis and Therapy Guidance

YUN-SHENG CHEN, DOUG YEAGER AND STANISLAV Y. EMELIANOV

Introduction	139
Operation Principle (Theory)	141
Photoacoustic Anatomical and Functional Imaging: Imaging Cancer with Endogenous Contrast	145
Photoacoustic Molecular Imaging: Imaging Cancer with Exogenous Contrast	148
Photoacoustic Image-Guided Cancer Therapies	152
Outlook	152
References	155

III

IMAGING-GUIDED THERAPY

10. Multimodality Image-Guided Lung Intervention Systems

KONGKUO LU, TIANCHENG HE, SHENG XU, MIGUEL VALDIVIA Y ALVARADO AND ZHONG XUE

Introduction	161
Medical Imaging for Minimally Invasive Intervention	162
Interventional Device Tracking	167
Image-Guided Lung Intervention	168
Conclusion	183
Acronyms and Abbreviations	183
References	183

11. Label-Free Molecular Vibrational Imaging for Cancer Diagnosis

LIANG GAO AND STEPHEN T.C. WONG

Introduction	187
Diagnostic Imaging of Prostate Gland and Cavernous Nerves Using CARS	189
CARS for Differential Diagnosis of Human Lung Cancer	192
Suppression of Four-Wave Mixing in Multimode Fibers for Fiber-Delivered CARS Imaging	194
Conclusions and Future Directions	197
Acknowledgments	198
Acronyms and Abbreviations	198
References	198

12. Multimodality Image-Guided Treatment

FRANKLIN C. WONG AND MARSHALL E. HICKS

Introduction	201
Imaging Modalities in Clinical Cancer Practice	202
Locoregional Cancer Therapy in Clinical Practice	203
Image-Guided Therapy and Multimodality Image-Guided Treatment	203
Possibilities of Multimodality Image-Guided Treatment	206
Limitations of and Requirements for Successful Deployment of Multimodality Image-Guided Treatment	207
Conclusion	209
Acronyms and Abbreviations	209
References	210

13. Medical Robotics for Cellular and Molecular Imaging

TOU PIN CHANG AND GUANG-ZHONG YANG

Overview	213
Confocal Endomicroscopy for Detection of Neoplasia	214
Challenges Faced by Confocal Endomicroscopy	216
Robotic Assistance and Computer-Aided Diagnosis	219
Future Work	223
References	223

IV

THERANOSTIC PLATFORMS

14. Porphyrins for Imaging, Photodynamic Therapy, and Photothermal Therapy

TRACY W. LIU, ELIZABETH HUYNH, THOMAS D. MACDONALD AND GANG ZHENG

Optical Imaging, Photodynamic Therapy, and Photothermal Therapy	229
Porphyrins	230
List of Acronyms and Abbreviations	248
References	248

15. Magnetic Resonance Imaging and Alternating Magnetic Fields

DON N. HO

Introduction	255
Key Concepts	256
Magnetic Nanoparticles as Contrast Agents for MRI Application	260
Magnetic Nanoparticles for Therapeutic Applications	262
Prospects and Conclusion	266
References	266

16. Ultrasound for Gene/Drug Delivery

SHAO-LING HUANG AND DAVID D. MCPHERSON

Barriers to Drug and Gene Delivery to Tumors	269
Biophysics of Therapeutic Ultrasound	271

Ultrasound-Facilitated Drug and Gene Delivery	271
Ultrasound-Responsive Nanoparticles as Drug and Gene Delivery Carriers	273
Therapeutic Applications of Drug and Gene Delivery	278
Potential Pitfalls in Ultrasound-Mediated Delivery into Tumor Tissue	280
Conclusions	280
Acknowledgments	280
References	281

17. Radionuclides for Imaging and Therapy in Oncology

IRINA VELIKYAN

Introduction	286
Imaging Techniques and Radionuclides	287
Radiotherapy	291
Selection of Radionuclides	292
Theranostics: Dual/Pair Radionuclides	294
Biomarkers and Radiopharmaceutical Development	296
Radiopharmaceuticals in Oncology	298
Conclusion	314
References	314

18. Noble Metal Nanoparticle Platform

JINGYI CHEN

Introduction	327
Physical, Chemical, and Biological Properties	328
Case Studies	332
Opportunities and Challenges	342
Acknowledgments	343
References	343

19. Cancer Theranostics with Carbon-Based Nanoplatfoms

TAPAS R. NAYAK, YIN ZHANG AND WEIBO CAI

Introduction	347
Fullerenes	348
Carbon Nanotubes	351
Graphene	354
C-Dots	356
Toxicity of Carbon Nanomaterials	356
Conclusion	358
Abbreviations	359
References	359

20. Silica Nanoparticle Platform

JEFFREY S. SOURIS, NAI-TZU CHEN, SHIH-HSUN CHENG,
CHIN-TU CHEN AND LEU-WEI LO

Introduction	363
Biocompatibility	364
Nanoplatfom Properties and Their Role in Biocompatibility	365
Silica Toxicity	368
Synthesis and Surface Modification of Silica Nanoparticles	371
Silica Nanoparticle Nanotheranostics	373
Conclusions	386
References	387

21. Quantum Dots for Traceable Therapeutic Delivery

CARL D. WALKEY AND WARREN C.W. CHAN

Introduction	393
Design and Synthesis of Theranostic Quantum Dots	395
Applications of Theranostic Quantum Dots	399
Barriers to the Clinical Translation of Theranostic Quantum Dots	408
Perspectives and Conclusions	412
References	413

22. Polymer- and Protein-Based Nanotechnologies for Cancer Theranostics

XI ZHU, EMMA L.B. ANQUILLARE, OMID C. FAROKHZAD
AND JINJUN SHI

Introduction	419
Polymer-Based Theranostic Platform	420
Protein-Based Theranostic Platforms	429
Opportunities and Challenges	432
Acknowledgments	433
References	433

OTHER

23. Clinical Translation and Regulations of Theranostics

MARY K. CLANCY

Introduction	439
Nanomedicine: The Vehicle	440
Molecular Imaging Probes: Linkage and Diagnostic	441
Biomarkers: The Target	442
Anticancer: Therapy	443
Determining Regulatory Requirements	443
Early Phase Trials	444
Investigational Drug Application	445
Combination Products	447
Companion Products	448
Some Alternate Paths to Regulatory Approval	448
Institutional Review Board	449
Reducing Bias	451
Conclusion	452
Glossary	453
Clinical Trial Phases Devices	453
Clinical Trial Phases (Drugs)	453
References	454

24. Scale-Up Production of Theranostic Nanoparticles

DONG NYOUNG HEO, KUNG HYUN MIN, GI HYUN CHOI,
IL KEUN KWON, KINAM PARK AND SANG CHEON LEE

Introduction	457
Current Preparation Methods of Theranostic Nanoparticles	458
Current Scale-Up Processes	462
Pilot Plant Design for Theranostic Nanoparticles	465

Sterilization	467
Summary and Future Perspectives	468
Acknowledgment	468
References	468

25. Market Considerations for Nanomedicines and Theranostic Nanomedicines

ARCHIE A. ALEXANDER AND FABRICE JOTTERAND

Introduction	472
Nanotechnologies Enabling Technologies	473
Nanotechnology Applications in Medicine and Business Model Selection	482
Nanotechnology and Nanomedicine Patenting Systems	483
Nanotechnology and Nanomedicine Regulatory, Legal, Ethical, and Policy Issues	484
Conclusion	487
Glossary	487
Abbreviations and Acronyms	488
References	489

26. Application of Theranostics to Measure and Treat Cell Heterogeneity in Cancer

SOPHIE A. LELIÈVRE, KURT B. HODGES AND PIERRE-ALEXANDRE VIDI

Introduction	494
Different Facets of Cellular Heterogeneity in Cancer	496
Tools to Detect and Measure Cell Heterogeneity	502
New Directions for the Management of Cell Heterogeneity in Cancer Via the Development of Theranostics	506
Conclusion	511
Acknowledgments	512
Glossary	512
Acronyms and Abbreviations	513
References	513

Index 517